2. Academic Validation
  3. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

  • J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739.
D Ross Camidge 1,  Fabrice Barlesi 2 3,  Jonathan W Goldman 4,  Daniel Morgensztern 5,  Rebecca Heist 6,  Everett Vokes 7,  Alex Spira 8,  Eric Angevin 9,  Wu-Chou Su 10,  David S Hong 11,  John H Strickler 12,  Monica Motwani 13,  Martin Dunbar 13,  Apurvasena Parikh 14,  Elysa Noon 13,  Vincent Blot 13,  Jun Wu 13,  Karen Kelly 15
Affiliations

Affiliations

  • 1 University of Colorado Cancer Center, Aurora, CO.
  • 2 Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Inserm U911 CRO2, Marseille, France.
  • 3 Medical Oncology Department, Gustave Roussy, Villejuif, France.
  • 4 David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • 5 Washington University School of Medicine, St Louis, MO.
  • 6 Massachusetts General Hospital Cancer Center, Boston, MA.
  • 7 University of Chicago Medicine, Chicago, IL.
  • 8 Virginia Cancer Specialists Research Institute, Fairfax, VA.
  • 9 Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.
  • 10 National Cheng Kung University Hospital, Tainan, Taiwan.
  • 11 The University of Texas MD Anderson Cancer Center, Houston, TX.
  • 12 Duke University Medical Center, Durham, NC.
  • 13 AbbVie Inc, North Chicago, IL.
  • 14 AbbVie Inc, Redwood City, CA.
  • 15 University of California Davis Comprehensive Cancer Center, Sacramento, CA.
PMID: 36288547 DOI: 10.1200/JCO.22.00739
Abstract

Purpose: Overexpression of c-Met protein and epidermal growth factor receptor (EGFR) mutations can co-occur in non-small-cell lung Cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable safety profile and antitumor activity as monotherapy. Herein, we report the results of a phase Ib study (ClinicalTrials.gov identifier: NCT02099058) evaluating Teliso-V plus erlotinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with c-Met-positive (+) NSCLC.

Patients and methods: This study evaluated Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily) in adult patients (age ≥ 18 years) with c-Met+ NSCLC. Later enrollment required presence of an EGFR-activating mutation (EGFR-M+) and progression on a prior EGFR TKI. End points included safety, pharmacokinetics, objective response rate (ORR), and progression-free survival (PFS). The efficacy-evaluable population consisted of c-Met+ patients (confirmed histology [H]-score ≥ 150) who had at least one postbaseline scan; c-Met+ patients with H-scores ≥ 225 were classified as c-Met high.

Results: As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all efficacy-evaluable patients was 5.9 months (95% CI, 2.8 to not reached). ORR for EGFR-M+ patients (n = 28) was 32.1%. Of EGFR-M+ patients, those who were c-Met high (n = 15) had an ORR of 52.6%. Median PFS was 6.8 months for non-T790M+ and for those whose T790M status was unknown, versus 3.7 months for T790M+.

Conclusion: Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with EGFR-M+, c-Met+ NSCLC.

Figures
Products